

NCT ID	NCT06493760
Title	A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Phase	Phase 2
Date Added	2024-07-10
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03600883
Title	A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreak 100)
Phase	Phase 1, Phase 2
Date Added	2018-07-26
Location	California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Indiana, United States Maryland, United States Massachusetts, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Brazil Canada France Germany Greece Hungary Japan Korea, Republic of Portugal Romania Spain Switzerland
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Anti PD-1/L1, Midazolam, Sotorasib
Tags	MSS/ MMRp
NCT ID	NCT06055439

Title	A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Phase	Phase 1, Phase 2
Date Added	2023-09-26
Location	Georgia, United States Illinois, United States Pennsylvania, United States Tennessee, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06011772
Title	A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Phase	Early Phase 1
Date Added	2023-08-25
Location	New York, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Suspended
Drugs	fluorouracil, Irinotecan, Leucovorin, oxaliplatin
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06412198
Title	A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Phase	Phase 1, Phase 2
Date Added	2024-05-14
Location	Massachusetts, United States Texas, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Adagrasib, cemiplimab, cetuximab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05865535
Title	A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia
Phase	Phase 1
Date Added	2023-05-19
Location	California, United States Florida, United States Georgia, United States Nebraska, United States New York, United States Oregon, United States South Carolina, United States Tennessee, United States Texas, United States
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting

Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06010901
Title	A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
Phase	Phase 1
Date Added	2023-08-25
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Anlotinib hydrochloride capsules, Penpulimab Injection, TQB2618 injection
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05973487
Title	A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2023-08-03
Location	Arizona, United States California, United States Connecticut, United States Florida, United States Illinois, United States Kentucky, United States Michigan, United States Minnesota, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06856837
Title	– IKF/AIO-QUINTIS – Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Phase	Phase 2
Date Added	2025-03-04
Location	Austria Germany
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSS/ MMRp